Nitrous Oxide as Treatment for Major Depression - a Pilot Study
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
Major depressive disorder (MDD) is a global medical problem with significant shortcomings in
current therapy. Chief among these is the delay between initiation of pharmacologic therapy
and clinical improvement in symptoms. Recently ketamine, an NDMA-receptor antagonist has been
shown to rapidly and effectively reverse the symptoms of MDD. Nitrous oxide, another
NMDA-receptor antagonist, may produce the same effect with a cleaner side-effect profile and
perhaps without the need for intravenous access and anesthesia personnel. Therefore, we
propose conducting a pilot randomized placebo controlled double-blind crossover study in
which patients will receive up to 50% nitrous oxide in oxygen or up to 50% oxygen in air for
a period of one hour in addition to standard medical therapy. Depression severity will be
assessed by a blinded observer pre-treatment, 30 minutes and 2 hours post treatment using the
Hamilton depression rating scale.